| ID Source | ID |
|---|---|
| PubMed CID | 16118986 |
| CHEMBL ID | 2430359 |
| SCHEMBL ID | 20471937 |
| MeSH ID | M0574873 |
| Synonym |
|---|
| pf-00562271 , |
| chembl2430359 , |
| unii-fk2m84h8ui |
| fk2m84h8ui , |
| 939791-38-5 |
| methanesulfonamide, n-(3-(((2-((2,3-dihydro-2-oxo-1h-indol-5-yl)amino)-5- (trifluoromethyl)-4-pyrimidinyl)amino)methyl)-2-pyridinyl)-n-methyl-, benzenesulfonate (1:1) |
| S2672 |
| n-methyl-n-(3-((2-(2-oxoindolin-5-ylamino)-5-(trifluoromethyl)pyrimidin-4-ylamino)methyl)pyridin-2-yl)methanesulfonamide benzenesulfonate |
| pf-562271 (besylate) |
| HY-10458 |
| pf-562271 besylate |
| pf 562271 besylate |
| n-methyl-n-(3-(((2-((2-oxoindolin-5-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)methyl)pyridin-2-yl)methanesulfonamide benzenesulfonate |
| AC-27465 |
| AKOS025401942 |
| n-methyl-n-(3-(((2-((2-oxoindolin-5-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)methyl)pyridin-2-yl)methanesulfonamide benzene sulfonate |
| J-523694 |
| mfcd14105612 |
| n-[3-[[[2-[(2,3-dihydro-2-oxo-1h-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]-2-pyridinyl]-n-methyl-methanesulfonamide benzenesulfonate |
| DTXSID40240064 |
| EX-A573 |
| HMS3651N09 |
| pf-00562271 besylate |
| pf-562271 phso3h salt |
| pf-562,271, >=98% (hplc) |
| SW219484-1 |
| SCHEMBL20471937 |
| FT-0700417 |
| 939791-38-5 (besylate) |
| lklwtlxtovzfae-uhfffaoysa-n |
| pf-562271 (benzesulfonate salt) |
| n-methyl-n-{3-[({2-[(2-oxo-2,3-dihydro-1h-indol-5-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl}amino)methyl]pyridin-2-yl}methanesulfonamide; benzenesulfonic acid |
| AS-75267 |
| BCP14770 |
| pf-562271 benzenesulfonate |
| pf 00562271-26 |
| methanesulfonamide, n-(3-(((2-((2,3-dihydro-2-oxo-1h-indol-5-yl)amino)-5-(trifluoromethyl)-4-pyrimidinyl)amino)methyl)-2-pyridinyl)-n-methyl-, benzenesulfonate |
| pf 562271 [who-dd] |
| SB12448 |
| CCG-270344 |
| benzenesulfonic acid;n-methyl-n-[3-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]methyl]pyridin-2-yl]methanesulfonamide |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1725064 | Protac activity at CRBN/FAK in mouse TM3 cells assessed as reduction in FAK autophosphorylation at tyr 397 residue at 3 uM after 8 hrs by Western blot analysis | 2020 | ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10 | Design, Synthesis, and Evaluation of Highly Potent FAK-Targeting PROTACs. |
| AID1529871 | Antiproliferative activity against human HepG2 cells after 2 days by spectrophotometric analysis | 2018 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24 | Design, synthesis, and biological evaluation of novel aminopyrimidinylisoindolines as AXL kinase inhibitors. |
| AID1529870 | Antiproliferative activity against human OVCAR3 cells after 2 days by spectrophotometric analysis | 2018 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24 | Design, synthesis, and biological evaluation of novel aminopyrimidinylisoindolines as AXL kinase inhibitors. |
| AID1725055 | Protac activity at CRBN/FAK in human PA1 cells assessed as FAK degradation at 10 uM after 8 hrs | 2020 | ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10 | Design, Synthesis, and Evaluation of Highly Potent FAK-Targeting PROTACs. |
| AID1529867 | Antiproliferative activity against human A549 cells after 2 days by spectrophotometric analysis | 2018 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24 | Design, synthesis, and biological evaluation of novel aminopyrimidinylisoindolines as AXL kinase inhibitors. |
| AID1529869 | Antiproliferative activity against human HeLa cells after 2 days by spectrophotometric analysis | 2018 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24 | Design, synthesis, and biological evaluation of novel aminopyrimidinylisoindolines as AXL kinase inhibitors. |
| AID1529868 | Antiproliferative activity against human U87MG cells after 2 days by spectrophotometric analysis | 2018 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24 | Design, synthesis, and biological evaluation of novel aminopyrimidinylisoindolines as AXL kinase inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.19) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (20.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||